Peripheral Nerve Stimulation and Peripheral Nerve Field Stimulation

Table of Contents
Coverage Policy .................................................. 1
Overview.............................................................. 1
General Background ........................................... 1
Coding/Billing Information ................................. 4
References .......................................................... 5

Related Coverage Resources
Electric Stimulation for Pain, Swelling and Function in a Clinic Setting
Electrical Stimulation Therapy and Home Devices
Gastric Pacing/Gastric Electrical Stimulation (GES)
Headache and Occipital Neuralgia Treatment
Sacral Nerve and Tibial Nerve Stimulation for Urinary Voiding Dysfunction, Fecal Incontinence and Constipation

INSTRUCTIONS FOR USE
The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

Coverage Policy
Peripheral nerve stimulation (PNS) and peripheral nerve field stimulation (PNFS) are considered experimental, investigational or unproven.

Overview
This Coverage Policy addresses peripheral nerve stimulation (PNS) and peripheral nerve field stimulation (PNFS) for treatment of pain conditions.

General Background
Peripheral Nerve Stimulation (PNS)
Percutaneous peripheral nerve stimulation (PNS) or percutaneous peripheral nerve stimulation, involves the implantation of electrodes near or on a peripheral nerve that is identified as transmitting pain to a specific area of the body. This is proposed for the treatment of chronic, refractory pain that is nonresponsive to conservative treatments. Chronic pain conditions for which PNS has been used include: hemiplegic shoulder pain, back pain, carpal tunnel syndrome; causalgia, complex regional pain syndrome, failed back syndrome, fibromyalgia,
hemiplegic shoulder pain, brachial plexus injuries, post-trauma pain, subacromial impingement syndrome, post-amputation pain, postherpetic neuralgia, stroke, testicular pain, and trigeminal neuropathy (Wilson, et al., 2014; Stevanato, et al., 2014; Reverberi, et al., 2014; Stidd, 2012; International Neuromodulation Society [INS], 2012). There is insufficient evidence to support the safety and effectiveness of PNS for the treatment of any indication including chronic pain.

PNS systems include a neurostimulator (pulse generator), leads (thin wires with electrodes), a controller (remote control device that allows the patient to control the device), and a programmer that is a remote control device that allows a medical professional to make adjustments to the settings of the pulse generator. The leads are positioned and connected to the generator. The electrodes are not permanently implanted as in spinal cord stimulation. A trial of PNS is indicated prior to permanent implantation of the generator. If the trial is successful (defined has >50% response rate in pain reduction), the generator is permanently implanted in the chest, abdomen or buttocks.

**U.S. Food and Drug Administration - PNS**

The Sprint Peripheral Nerve Stimulation (PNS) System (SPR Therapeutics, Cleveland, Ohio) received 510(k) approval in 2017 as a class II device. The indications for use include:

- Symptomatic relief of chronic, intractable pain, post-surgical and post-traumatic acute pain;
- Symptomatic relief of post-traumatic pain;
- Symptomatic relief of post-operative pain.

The Sprint PNS System is not intended to treat pain in the craniofacial region.

StimQ Peripheral Nerve Stimulator (PNS) (Stimwave Technologies Incorporated, Ft. Lauderdale FL) system received 510(k) approval in 2017 as a class II device. The approval included indications for use: the device is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as the sole mitigating agent, or as an adjunct to other modes of therapy used in a multidisciplinary approach. The StimQ PNS System is not intended to treat pain in the craniofacial region. The StimQ Trial Lead Kit is only used in conjunction with the StimQ Stimulator Receiver Kit. The trial devices are solely used for trial stimulation (no longer than 30 days) to determine efficacy before recommendation for a permanent (long term) device.

StimRouter Neuromodulation System (Bioness Inc., Valencia, CA) received 510(k) approval in 2015 as a class II device. The device is indicated for pain management in adults who have severe intractable chronic pain of peripheral nerve origin, as an adjunct to other modes of therapy (e.g., medication). It is not intended to treat pain in the craniofacial region.

**Literature Review- PNS**

There is insufficient evidence in the published peer-reviewed literature to support the safety and effectiveness of implanted PNS for any indication. Studies are primarily in the form of case reports, retrospective reviews and case series with small patient populations (n=7–15) (Gilmore, et al., 2018; Wilson, et al., 2014; Wilson et al., 2017; Stevanato, et al., 2014; Reverberi, et al., 2014; Stidd, 2012). A prospective, multicenter, randomized, double-blind, partial crossover study was conducted to assess safety and efficacy of the StimRouter System for use in the treatment of severe, intractable pain of peripheral nerve origin associated with posttraumatic or postsurgical neuralgia, exclusive of the craniofacial region (Deer, et al., 2016). Ninety-four patients were randomized to treatment group (n=45) or control group (n=49). Primary outcomes included pain relief and safety, measured by average pain at rest using a numerical rating scale (NRS) followed for three months, and safety, determined by assessment of adverse events (AEs) during the one-year study period. Treatment group received electrical stimulation from the StimRouter System and stable dosing of pain medications, while the Control group received no therapeutic stimulation and a stable dose of pain medications. At three months with patients receiving active stimulation achieved indicated higher response rate of 38% vs. the 10% rate found in the Control group (p = 0.0048). Improvement in pain was between the randomized groups, the Treatment group achieved a mean pain reduction of 27.2% from baseline to month three compared to a 2.3% reduction in the Control group (p<0.0001). Safety, assessed throughout the trial and with follow-up to one year, demonstrated no serious adverse events related to the device. For safety follow-up, 15 did not participate in the six- and 12-month follow-up and 33 patients at 12 month follow-up, representing an attrition of 51%.

**Peripheral nerve field stimulation (PNFS)**
Peripheral nerve field stimulation (PNFS), also known as subcutaneous peripheral field stimulation, is a recent technology proposed for the treatment of chronic cervical, thoracic, or lumbar pain. Electrode leads are placed in subcutaneous tissue around the painful area, and electrical current is applied to create stimulation in the area, or "field," of pain. This technique is different from peripheral nerve stimulation (PNS), in which specific peripheral nerves are targeted. In peripheral nerve field stimulation, a field of pain is targeted rather than specific nerves. The electrodes are placed in the skin either through an open or percutaneous approach. Imaging guidance is included, when performed. The electrode is placed subcutaneously at the site of maximum pain rather than at the site of the nerve. This technique also referred to as subcutaneous target stimulation (STS) or peripheral nerve field stimulation (PNFS) involves a temporary trial period in which an electrode is placed subcutaneously by open or percutaneous approach, is secured in place with suture, and is then attached to a generator for approximately two to 14 days. A trial is considered successful if there is at least 50% pain reduction. Following a successful temporary trial the device is implanted.

**U.S. Food and Drug Administration (FDA) - PNFS:**
FDA approval for specific PNFS devices was not found on the FDA site. However, PNFS can be carried out using leads and electrodes that are primarily designed for spinal cord stimulation and may be considered an off-label use of these devices.

**Literature Review- (PNFS)**
Randomized controlled clinical trial data, and meta-analyses are lacking in the published, peer-reviewed scientific literature and there is insufficient evidence to determine safety and effectiveness of this therapy. Published peer-reviewed clinical trial data is primarily limited to case series and prospective and retrospective reviews and studies with small number of subjects (McRoberts, et al., 2013; Petersen, et al., 2014; Verrills, et al., 2011; Mitchell, et al., 2016).

**Professional Societies/Organizations**
The American Society of Anesthesiologists Task Force on Chronic Pain Management; American Society of Regional Anesthesia and Pain Medicine published practice guidelines for chronic pain management (2010). The guidelines noted regarding subcutaneous peripheral nerve stimulation that studies with observational findings indicate that subcutaneous peripheral nerve stimulation can provide pain relief for assessment periods ranging from four months to two years (Category B2 evidence).

Category B2 evidence: the literature contains noncomparative observational studies with associative (e.g., relative risk and correlation) or descriptive statistics.

**Centers for Medicare & Medicaid Services (CMS)**
- National Coverage Determinations (NCDs) National Coverage Determination (NCD) for Electrical Nerve Stimulators (160.7) 8/7/1995. The NCD is broader in scope than the Coverage Policy. Refer to the CMS NCD table of contents link in the reference section.
- Local Coverage Determinations (LCDs): Peripheral Nerve Stimulation. (L34328) (2019). The Coverage Policy is broader in scope than the LCD. Refer to the CMS LCD table of contents link in the reference section.

**Use Outside of the US**
E uropean Federation of Neurological Societies (EFNS): EFNS guidelines on neurostimulation therapy for neuropathic pain evaluate the evidence for techniques including PNS and concluded that they could not draw any conclusion for PNS (Cruccu, et al., 2007). A 2016 update to these guidelines by the European Academy of Neurology examined central neurostimulation therapy in chronic pain conditions and noted that the recommendations were restricted to central neurostimulation because trials on peripheral stimulations are characterized by a great heterogeneity of methods (Cruccu, et al., 2016).

**National Institute for Health and Care Excellence (NICE):** NICE (2013) published guidance regarding peripheral nerve field stimulation for chronic low back pain. NICE recommendations note that evidence on efficacy is very limited, in both quality and quantity. Likewise, evidence on safety is also limited and there is a risk of complications from any implanted device. Therefore this procedure should only be used with special arrangements for clinical governance, consent and audit or research.
**Coding/Billing Information**

**Note:** 1) This list of codes may not be all-inclusive.  
2) Deleted codes and codes which are not effective at the time the service is rendered may not be eligible for reimbursement.

**Considered Experimental/Investigational/Unproven for peripheral nerve stimulation (PNS) and peripheral nerve field stimulation (PNFS):**

<table>
<thead>
<tr>
<th>CPT® Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>64555</td>
<td>Percutaneous implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve)</td>
</tr>
<tr>
<td>64575</td>
<td>Incision for implantation of neurostimulator electrode array; peripheral nerve (excludes sacral nerve)</td>
</tr>
<tr>
<td>64585</td>
<td>Revision or removal of peripheral neurostimulator electrode array</td>
</tr>
<tr>
<td>64590</td>
<td>Insertion or replacement of peripheral or gastric neurostimulator pulse generator or receiver, direct or inductive coupling</td>
</tr>
<tr>
<td>64595</td>
<td>Revision or removal of peripheral or gastric neurostimulator pulse generator or receiver</td>
</tr>
<tr>
<td>64999</td>
<td>Unlisted procedure, nervous system</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>HCPCS Codes</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>C1767</td>
<td>Generator, neurostimulator (implantable), non-rechargeable</td>
</tr>
<tr>
<td>C1778</td>
<td>Lead, neurostimulator (implantable)</td>
</tr>
<tr>
<td>C1787</td>
<td>Patient programmer, neurostimulator</td>
</tr>
<tr>
<td>C1816</td>
<td>Receiver and/or transmitter, neurostimulator (implantable)</td>
</tr>
<tr>
<td>C1820</td>
<td>Generator, neurostimulator (implantable), with rechargeable battery and charging system</td>
</tr>
<tr>
<td>C1822</td>
<td>Generator, neurostimulator (implantable), high frequency, with rechargeable battery and charging system</td>
</tr>
<tr>
<td>C1883</td>
<td>Adaptor/extension, pacing lead or neurostimulator lead (implantable)</td>
</tr>
<tr>
<td>C1897</td>
<td>Lead, neurostimulator test kit (implantable)</td>
</tr>
<tr>
<td>L8679</td>
<td>Implantable neurostimulator, pulse generator, any type</td>
</tr>
<tr>
<td>L8680</td>
<td>Implantable neurostimulator electrode, each</td>
</tr>
<tr>
<td>L8681</td>
<td>Patient programmer (external) for use with implantable programmable neurostimulator pulse generator, replacement only</td>
</tr>
<tr>
<td>L8682</td>
<td>Implantable neurostimulator radiofrequency receiver</td>
</tr>
<tr>
<td>L8683</td>
<td>Radiofrequency transmitter (external) for use with implantable neurostimulator radiofrequency receiver</td>
</tr>
<tr>
<td>L8685</td>
<td>Implantable neurostimulator pulse generator, single array, rechargeable, includes extension</td>
</tr>
<tr>
<td>L8686</td>
<td>Implantable neurostimulator pulse generator, single array, non-rechargeable, includes extension</td>
</tr>
<tr>
<td>L8687</td>
<td>Implantable neurostimulator pulse generator, dual array, rechargeable, includes extension</td>
</tr>
<tr>
<td>L8688</td>
<td>Implantable neurostimulator pulse generator, dual array, non-rechargeable, includes extension</td>
</tr>
<tr>
<td>L8689</td>
<td>External recharging system for battery (internal) for use with implantable neurostimulator, replacement only</td>
</tr>
<tr>
<td>L8695</td>
<td>External recharging system for battery (external) for use with implantable neurostimulator, replacement only</td>
</tr>
</tbody>
</table>

References


“Cigna Companies” refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Cigna Behavioral Health, Inc., Cigna Health Management, Inc., QualCare, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. © 2019 Cigna.